In our study, we performed nanostring assays to evaluate pathway-associated gene expression and calculate MEK signature using six genes, DUSP4, DUSP6, ETV4, ETV5, PHLDA1, and SPRY2, in advanced GC patients. The gene discussed is SPRY2; the disease is gastric cancer.